DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3h3w79/tralokinumab) has announced the addition of the "Tralokinumab (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
AstraZeneca's tralokinumab is in Phase II of development for severe, persistent, uncontrolled asthma despite standard-of-care therapy and failing third-line treatment, such as a high-dose ICS/LABA combination. Tralokinumab is an IgG4 humanized mAb against IL-13, which is a pleiotropic cytokine of the Th2 cell response. IL-13 is a key target for new anti-asthma therapeutic strategies because of its involvement, together with IL-4, in several aspects of airway inflammation and remodeling, including mucus production, IgE synthesis, recruitment of eosinophils and basophils, as well as proliferation of bronchial fibroblasts and airway smooth muscle cells.
- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tralokinumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tralokinumab for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Unmet Need and Opportunity
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/3h3w79/tralokinumab